Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01143090 · ClinicalTrials.gov registry record · Phase 3
A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 149
- Enrollment target
NCT01143090 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 149 participants.
The verdict
NCT01143090, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 149 participants
- Enrollment target
Study Summary
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The purpose of this study is to characterize the long-term safety and tolerability of lurasidone in subjects with schizophrenia or schizoaffective disorder and to allow for continued treatment for subjects completing the core study (D1050289-NCT01143077).
Interventions
- DRUG Lurasidone HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2010-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01143090
The ClinicalTrials.gov registry entry for NCT01143090 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lurasidone HCl is the first listed.
NCT01143090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01143090 about?
NCT01143090 is a clinical study titled "A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder". Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The purpose of this study is to characterize the long...
What is the current status of trial NCT01143090?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 149 participants. The study started on 2010-08.
What interventions are being tested in trial NCT01143090?
The interventions under investigation include: Lurasidone HCl (DRUG).
Who is sponsoring clinical trial NCT01143090?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.